Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Recommendation of “Hold” from Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE) has earned a consensus rating of “Hold” from the nineteen ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $8.81.

Several brokerages have recently issued reports on SAGE. Bank of America initiated coverage on Sage Therapeutics in a report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price target for the company. Wedbush reiterated a “neutral” rating and issued a $6.00 target price on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Canaccord Genuity Group dropped their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, February 12th. HC Wainwright restated a “neutral” rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Stifel Nicolaus decreased their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a report on Monday, December 16th.

Sage Therapeutics Stock Up 0.7 %

SAGE stock opened at $8.66 on Friday. The company has a 50 day moving average of $7.45 and a two-hundred day moving average of $6.73. The company has a market cap of $532.43 million, a price-to-earnings ratio of -1.31 and a beta of 0.82. Sage Therapeutics has a 12-month low of $4.62 and a 12-month high of $19.34.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. On average, research analysts anticipate that Sage Therapeutics will post -3.52 EPS for the current year.

Institutional Trading of Sage Therapeutics

Hedge funds have recently bought and sold shares of the stock. Caligan Partners LP bought a new stake in shares of Sage Therapeutics in the 4th quarter valued at approximately $16,575,000. Boothbay Fund Management LLC acquired a new stake in Sage Therapeutics in the 4th quarter valued at $7,540,000. State Street Corp grew its position in Sage Therapeutics by 18.2% in the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after acquiring an additional 451,377 shares during the period. Federated Hermes Inc. raised its stake in Sage Therapeutics by 63.7% during the fourth quarter. Federated Hermes Inc. now owns 1,105,779 shares of the biopharmaceutical company’s stock worth $6,004,000 after acquiring an additional 430,432 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Sage Therapeutics by 103.1% during the fourth quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company’s stock valued at $2,509,000 after acquiring an additional 234,528 shares during the period. 99.22% of the stock is owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.